---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040294"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:06:06.789085+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gemini priming attenuates inflammation in human PBMCs; Phase 1b data expected mid-2025

## Summary
- Gemini significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines vs. placebo in PBMCs challenged with HMGB-1 and LPS.
- Revelation anticipates demonstrating same protective effect in cells from CKD patients in ongoing Phase 1b PRIME study.
- Top-line safety, tolerability, and cellular protection data from Phase 1b expected by mid-2025.
- Results support future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.
- CEO James Rolke called results 'game-changing' for Gemini's potential in target indications.

## SEC filing metadata
- accession: 0000950170-25-040294
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017025040294/0000950170-25-040294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017025040294/revb-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040294
- JSON: https://secwatch.observer/filing/0000950170-25-040294.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.